Vitro studies shows that lenalidomide ( CAS: 191732-72-6)
is not the substrate for liver metabolic enzymes. Lenalidomide prototype drug is the main component in the human body's circulation. There are two identified metabolites: 5-hydroxyl-lenalidomide
. The concentration of each metabolite is less than 5% of the prototype drug level in the cycle.
About 90% and 4% of the radioactive doses are removed from urine and feces after giving a single dose of [14C]- lenalidomide ( CAS: 191732-72-6, 25mg)
per os to the healthy subjects. About 82% of the radioactive dose is unmetabolized lenalidomide prototype drug, almost of which is excreted by urinary tract. The 5-hydroxyl-lenalidomide
respectively account for 4.59% and 1.83% of the excretion dose. The renal clearance rate of the lenalidomide is higher than the glomerular filtration rate, so there is at least some degree of active secretion about the lenalidomide ( CAS: 191732-72-6)
In the recommended dose range (5 ~ 25mg/day), the plasma half-life of healthy subjects and multiple myeloma patients is approximately 3 hours and 3 to 5 hours respectively.
Sinoway, the best lenalidomide manufacturer from China, devoted itself to supplying high quality lenalidomide with good price. Click here to buy lenalidomide